346 related articles for article (PubMed ID: 36243381)
1. Novel coronavirus mutations: Vaccine development and challenges.
Luo WR; Wu XM; Wang W; Yu JL; Chen QQ; Zhou X; Huang X; Pan HF; Liu ZR; Gao Y; He J
Microb Pathog; 2022 Dec; 173(Pt A):105828. PubMed ID: 36243381
[TBL] [Abstract][Full Text] [Related]
2. The variants of SARS-CoV-2 and the challenges of vaccines.
Han X; Ye Q
J Med Virol; 2022 Apr; 94(4):1366-1372. PubMed ID: 34890492
[TBL] [Abstract][Full Text] [Related]
3. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
[TBL] [Abstract][Full Text] [Related]
4. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.
Sharma O; Sultan AA; Ding H; Triggle CR
Front Immunol; 2020; 11():585354. PubMed ID: 33163000
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 Variants and Vaccine Development.
Zhao Z; Bashiri S; Ziora ZM; Toth I; Skwarczynski M
Viruses; 2024 May; 16(5):. PubMed ID: 38793638
[TBL] [Abstract][Full Text] [Related]
6. Modeling coronavirus spike protein dynamics: implications for immunogenicity and immune escape.
Kunkel G; Madani M; White SJ; Verardi PH; Tarakanova A
Biophys J; 2021 Dec; 120(24):5592-5618. PubMed ID: 34767789
[TBL] [Abstract][Full Text] [Related]
7. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
8. The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice.
Hu L; Xu Y; Wu L; Feng J; Zhang L; Tang Y; Zhao X; Mai R; Chen L; Mei L; Tan Y; Du Y; Zhen Y; Su W; Peng T
Viruses; 2022 Apr; 14(5):. PubMed ID: 35632595
[TBL] [Abstract][Full Text] [Related]
9. Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021.
Bui NN; Lin YT; Huang SH; Lin CW
Infect Genet Evol; 2022 Jan; 97():105164. PubMed ID: 34848355
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants.
Li C; Guo Y; Fang Z; Zhang H; Zhang Y; Chen K
Front Immunol; 2022; 13():804945. PubMed ID: 35572594
[TBL] [Abstract][Full Text] [Related]
11. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.
Zhang J; He Q; An C; Mao Q; Gao F; Bian L; Wu X; Wang Q; Liu P; Song L; Huo Y; Liu S; Yan X; Yang J; Cui B; Li C; Wang J; Liang Z; Xu M
Emerg Microbes Infect; 2021 Dec; 10(1):1598-1608. PubMed ID: 34278956
[TBL] [Abstract][Full Text] [Related]
12. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines.
Singh DD; Parveen A; Yadav DK
Front Cell Infect Microbiol; 2021; 11():777212. PubMed ID: 34970509
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of SARS-CoV-2 vaccine candidates.
Dong Y; Dai T; Wei Y; Zhang L; Zheng M; Zhou F
Signal Transduct Target Ther; 2020 Oct; 5(1):237. PubMed ID: 33051445
[TBL] [Abstract][Full Text] [Related]
16. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines.
Ambrosino D; Han HH; Hu B; Liang J; Clemens R; Johnson M; Siber G; Goldblatt D
J Infect Dis; 2022 Jan; 225(2):327-331. PubMed ID: 34888662
[TBL] [Abstract][Full Text] [Related]
18. Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy.
Rayati Damavandi A; Dowran R; Al Sharif S; Kashanchi F; Jafari R
Med Microbiol Immunol; 2022 Jun; 211(2-3):79-103. PubMed ID: 35235048
[TBL] [Abstract][Full Text] [Related]
19. Design of Replication-Competent VSV- and Ervebo-Vectored Vaccines Against SARS-CoV-2.
Liu Q; Ding Z; Lan J; Wong G
Methods Mol Biol; 2022; 2410():193-208. PubMed ID: 34914048
[TBL] [Abstract][Full Text] [Related]
20. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
